The homeodomain transcription factor vHNF1 plays an essential role in the patterning of the caudal segmented hindbrain, where it participates in the definition of the boundary between rhombomeres (r) 4 and 5 and in the specification of the identity of r5 and r6. Understanding the molecular basis of vHnf1 own expression therefore constitutes an important issue to decipher the regulatory network governing hindbrain patterning. We have identified a highly conserved 800-bp enhancer element located in the fourth intron of vHnf1 and whose activity recapitulates vHnf1 neural expression in transgenic mice. Functional analysis of this enhancer revealed that it contains two types of essential motifs, a retinoic acid response element and two half T-MARE sites, indicating that it integrates direct inputs from the retinoic acid signaling cascade and MAF-related factors. Our data suggest that MAFB, which is itself regulated by vHNF1, acts as a positive modulator of vHnf1 in r5 and r6, whereas another MAF-related factor is absolutely required for the expression of vHnf1 in both the hindbrain and the spinal cord. We propose a model accounting for the initiation and maintenance phases of vHnf1 expression and for the establishment of the r4/r5 boundary, based on cooperative contributions of Maf factors and retinoic acid signaling.
Introduction
The vertebrate hindbrain is subjected to a transient segmentation process along the anteroposterior (AP) axis that results in the establishment of a series of 7/8 metameric transversal territories called rhombomeres (r) (Lumsden and Keynes, 1989; Lumsden and Krumlauf, 1996) . This subdivision presages the stereotyped pattern of neuronal differentiation in the hindbrain (Clarke et al., 1998; Lumsden and Keynes, 1989) . It also underlies the pathways of neural crest cell migration into the branchial arches and participates in their patterning (Ghislain et al., 2003; Lumsden et al., 1991; Serbedzija et al., 1992; Trainor and Krumlauf, 2000; Trainor et al., 2002 and references therein), thus playing an essential role in craniofacial morphogenesis.
Numerous genes, including a large proportion of transcription factor genes, have been shown to present evolutionarily conserved, restricted patterns of expression along the AP axis, with limits corresponding to prospective or established rhombomere boundaries (reviewed in Lumsden and Krumlauf, 1996) , and many of them have been implicated at different levels of the segmentation process (see Chomette et al., 2006 for references) . Understanding the principles governing hindbrain segmentation will clearly require to decipher the details of the regulation of these segmentally restricted genes themselves. Although data are still limited on this matter, they suggest that the initial establishment and later evolution of their expression patterns result from the combination of at least three types of inputs: morphogenetic gradients of diffusible signaling molecules such as retinoic acid (RA), Fgf and Wnt (Dupe and Lumsden, 2001; Gavalas and Krumlauf, 2000; Kudoh et al., 2002; Marin and Charnay, 2000; Nordstrom et al., 2006; Walshe et al., 2002) , cross-regulations between the segmentally expressed genes (Maconochie et al., 1997; Manzanares et al., 1997; Sham et al., 1993) and autoregulatory mechanisms (Chomette et al., 2006; Manzanares et al., 2001; Popperl et al., 1995) .
vHnf1 (variant hepatocyte nuclear factor 1, also known as Hnf1β or Tcf2) is one of these evolutionarily conserved, segmentally restricted genes, playing an essential role in hindbrain development. It encodes a transcription factor with an atypical homeodomain, closely related to HNF1α (De Simone et al., 1991; Rey-Campos et al., 1991) . In the mouse neural tube vHnf1 expression is initiated at around embryonic day (E) 7.8 in the caudal hindbrain and spinal cord, and at E8 its anterior limit was shown to coincide with prospective r4/r5 boundary (Barbacci et al., 1999; Coffinier et al., 1999; Sirbu et al., 2005) , as in other vertebrate species (Aragon et al., 2005; Lecaudey et al., 2004; Sun and Hopkins, 2001) . Later this anterior limit progressively retracts posteriorly in the hindbrain and the spinal cord expression becomes restricted to the roof plate and a ventral region (Aragon et al., 2005; Barbacci et al., 1999; Coffinier et al., 1999; Lecaudey et al., 2004) . Knock-out of the mouse gene was shown to be lethal around E6 due to the absence of extraembryonic visceral endoderm where vHnf1 is also expressed (Barbacci et al., 1999; Coffinier et al., 1999) . Recent work in the zebrafish has shown that impairment of vHnf1 function leads to mis-specification of r5 and r6, which acquire r4-like identity (Hernandez et al., 2004; Sun and Hopkins, 2001; Wiellette and Sive, 2003) . More precisely, vHNF1 was shown to repress an r4 fate posterior to the r4/r5 boundary, to cooperate with Fgf signals from r4 in activating MafB expression in r5 and r6 and to cooperate with MAFB in establishing r5 and r6 identities, including the direct transcriptional activation of Krox20 in r5 (Chomette et al., 2006; Hernandez et al., 2004) .
Substantial evidence has accumulated to implicate the RA signaling pathway in the activation of vHnf1 expression and fixation of its anterior boundary. Depletion of RA during early embryogenesis, using mutations in the major RA synthesizing enzyme gene, Raldh2 (Hernandez et al., 2004; Sirbu et al., 2005) , or application of a specific RALDH2 molecular antagonist (Hernandez et al., 2004; Maves and Kimmel, 2005) , led to almost complete abolition of vHnf1 expression. Conversely, vHnf1 was ectopically induced in the anterior neural tube following elevation of the endogenous RA level obtained by treatment with RA (Maves and Kimmel, 2005; Sirbu et al., 2005) or by preventing RA degradation (Hernandez et al., 2007) . In addition, the fixation of the rostral limit of vHnf1 expression and therefore of the r4/r5 boundary has also been shown to involve a mechanism of mutual repression between vHNF1 and the Iro7 transcription factor (Lecaudey et al., 2004 ). However it is not known whether vHnf1 constitutes a direct target of RA signaling and/or Iro7, or whether their actions are relayed by other segmentally expressed genes. Indeed perturbation in the expression of Hox paralogous group 1 genes and of their associated factors genes, Pbx and Meis, have been shown to dramatically affect vHnf1 expression in zebrafish (Choe and Sagerstrom, 2004; Waskiewicz et al., 2002) and some of these genes have been shown to be under RA control (Gould et al., 1998; Langston and Gudas, 1992; Marshall et al., 1994) . Understanding the details of vHnf1 regulation therefore requires the identification of its direct upstream regulators. In the present work, to initiate such an analysis, we have searched for the cis-acting regulatory elements responsible for vHnf1 expression in the hindbrain and spinal cord. We have screened a 193-kb genomic region surrounding the mouse gene and identified a highly conserved 800-bp transcriptional enhancer element located in the fourth intron of vHnf1 and whose activity recapitulates vHnf1 neural expression in transgenic mice. Analysis of this enhancer revealed that it contains a conserved RA response element (RARE) essential for its activity, establishing that vHnf1 constitutes a direct target of RA signaling. The enhancer also contains two half T-MARE motifs and their mutation abolished enhancer activity. T-MARE and half T-MARE constitute binding sites for members of the MAF family of proteins that are basic-leucine zipper (bZIP) transcription factors belonging to the AP1 superfamily (for a review see Motohashi et al., 1997 Motohashi et al., , 2002 . MAF proteins can homo-and heterodimerize with each other as well as with other members of the AP1 family such as Jun and Fos (Kataoka et al., 1994; Matsushima-Hibiya et al., 1998) . Our data indicate that MAFB, which is itself regulated by vHNF1, acts as a positive modulator of vHnf1 in r5 and r6 and suggest the absolute requirement of (an)other MAF-related factor(s) for the regulation of vHnf1 in both the hindbrain and the spinal cord.
Materials and methods

DNA constructions and mutagenesis
BAC clone RPCI23-304H7 was obtained from a mouse genomic library at the Children's Hospital Oakland Research Institute (BACPAC Resources). Mouse fragments #2 to 5 were cloned by PCR from the BAC clone using primers indicated in Supplementary Table S1 . Chicken fragments #8 to 12 were cloned by PCR from chicken BAC clone CH261-68C12 (BACPAC resources) using primers indicated in Supplementary Table S1 . Mutagenesis of the RARE in fragment #5 was performed by PCR using primers indicated in Supplementary Table S1 . Mutagenesis of the MAF-binding sites (Manzanares et al., 2002) in fragment #5 was performed using the Quickchange Multi Site Directed Mutagenesis Kit (Stratagene) with primers indicated in Supplementary Table S1 . Fragments #2 to 12 were cloned into pBGZ40 (Yee and Rigby, 1993) upstream of the minimal β-globin promoter/lacZ reporter gene.
Generation of transgenic mice, genotyping and in ovo electroporation
Purification of fragments #2 to 7, 10 and 11 and microinjection of fertilized mouse eggs were performed as described previously (Ghislain et al., 2002; Sham et al., 1993) . Transgenic embryos were identified by PCR with primers indicated in Supplementary Table S1 . BAC RPCI23-304H7 DNA was isolated using alkaline lysis and cesium chloride gradient ultracentrifugation. It was co-injected as a supercoiled plasmid in fertilized mouse eggs together with a 1.5-kb vHnf1 minimal promoter-lacZ reporter fragment in equimolar amounts as described (Chomette et al., 2006) . Transgenic embryos were identified by PCR using the BAC vector and minimal promoter-lacZ reporter-specific primers indicated in Supplementary Table S1 . The kreisler allele (Frohman et al., 1993) was maintained in S129 background and construct #3 transgene in a mixed C57Bl6/ DBA2 background. In ovo electroporation into the chick neural tube was performed as previously described (Giudicelli et al., 2001 ) at stages HH8-9 and embryos were collected at HH11-13 for X-gal staining. Co-electroporation experiments with pAdRSV-vHNF1, pAdRSV-MAFB and pAdRSV-MAF-BR22E were carried out as previously described (Giudicelli et al., 2003) . Each electroporation experiment included a co-electroporation with a GFP reporter, pCMV-eGfp (0.2 μg/μl). Only embryos showing efficient eGFP expression from the midbrain to the spinal cord were retained for the analysis. Care and use of experimental animals involved in the present work were performed in accordance with French and European regulations.
RA treatment, whole-mount in situ hybridization and X-gal staining RA treatment was performed by feeding pregnant transgenic female mice at 7.5 days post coitum (dpc) as previously described (Conlon and Rossant, 1992) . Treated females were fed with retinoic acid diluted in DMSO and mixed with sunflower seed oil (Sigma). Control females were fed with DMSO alone mixed with oil. Embryos were collected for X-gal staining half or 1 day after RA treatment. Single and double whole-mount in situ hybridizations were performed as previously described (Giudicelli et al., 2001) , using mouse vHnf1 (Ott et al., 1991 )-and Krox20 (Wilkinson et al., 1989 )-specific probes. Alkaline phosphatase activity was revealed either in blue/purple or in orange/red using the NBT/BCIP and INT/BCIP substrates respectively (Roche). X-gal labeling and co-labeling together with in situ hybridization were performed on chicken and mouse embryos as previously described (Ghislain et al., 2003) , using Krox20 (Wilkinson et al., 1989) and Hoxb1 (Wilkinson et al., 1989) probes.
In vitro DNA-binding and in silico analyses
The mouse MAFB protein was expressed in Escherichia coli using the pET21 vector (Novagen). Extracts from control and MafB-expressing bacteria were prepared as described previously (Manzanares et al., 2002) . Band shift assays were performed on an SpeI fragment derived from wild-type or mutant versions of fragment #5 as described (Manzanares et al., 1997) . DNAse I footprinting experiments were performed on a BamHI-EcoRI subclone of fragment #5 as previously described (Manzanares et al., 2002) . Labeled fragments were purified by electrophoresis on a 6% polyacrylamide gel. To produce mouse RARβ and RXRα, COS-7 cells were transfected with pSG5-mRarβ or pSG5-mRxrα (kind gifts from C. Rochette-Egly) (Rochette-Egly et al., 1991) or co-transfected with both using the Fugene 6 Transfection Reagent (Roche). Nuclear extracts were prepared from control and transfected cells as previously described (Carpentier et al., 1997) , with the following modifications: complete Protease Inhibitor Cocktail (Roche) was added to buffers A and B and 10 μM ZnCl 2 to buffer B. Nuclear extracts were concentrated by ultrafiltration through Centrikon 30 microconcentrators (Amicon, Millipore) and stored at −80°C. Band shift was performed as previously described (Zechel et al., 1994) using a 65-bp oligonucleotide probe carrying wild-type or mutant versions of the vHnf1 RARE. For supershift analysis 1 μl of mouse ascite fluid antibody 8β10B2 or 4RX1D12 (kind gifts from C. Rochette-Egly), directed against mouse RARβ and RXRα respectively, was added to the mix (Rochette-Egly et al., 1991) . Sequence alignments were performed using Dotter (Sonnhammer and Durbin, 1995) , Pipmaker (Schwartz et al., 2000) and ClustalW softwares. Identification of RARE was obtained using Footer software (Corcoran et al., 2005) .
Results
Delimitation of the genomic region controlling vHnf1 expression in the neural tube
During mouse development, vHnf1 is expressed in the neural tube with a dynamic pattern whose extension is maximal around E8 and covers r5, r6 and the spinal cord ( Fig. 1A and Sirbu et al., 2005) . To identify the cis-acting regulatory elements that are responsible for this expression, we analyzed a large genomic region corresponding to the interval between the two genes flanking vHnf1, Abc1 and Ddx52. We selected a mouse BAC, clone RPCI23-304H7, that encompasses this genomic domain ( Fig. 2A) . To evaluate its transcriptional enhancing activity, this BAC clone was introduced into the mouse genome by transgenesis, together with a reporter construct, in which the lacZ gene is driven by the vHnf1 promoter with 1.5 kb of 5′ flanking sequences ( Fig. 2A ) and which does not give any specific expression on its own in transgenic mice (Silvia Cereghini, personal communication) . In half the embryos that co-integrated the BAC clone and the reporter construct ( Fig.  2A , transgene #1, n = 4), analysis of β-galactosidase activity by X-gal staining at E8 revealed expression in r5, r6 and the spinal cord (Fig. 1B) , a pattern very similar to that of the endogenous vHnf1 gene (Fig. 1A ). Of particular interest was the conservation of the rostral limit of expression at the level of the prospective r4/r5 boundary. These data indicate that cis-acting regulatory elements essential for vHnf1 neural expression are likely to be located in a region delimited by the Abc1 and Ddx52 loci in the mouse genome.
Since the vHnf1 neural expression pattern is conserved among vertebrates (Aragon et al., 2005; Lecaudey et al., 2004; Sirbu et al., 2005; Sun and Hopkins, 2001) , we hypothesized that the transcriptional enhancer elements responsible for this pattern should also be conserved among these species. We therefore performed a comparison of the genomic region between the mouse and the chick. Whereas the general organization is conserved (Figs. 2A, B) , the chick domain (37 kb) is much smaller than the mouse (193 kb). The chick Abc1/Ddx52 intergenic region was divided into four fragments (Fig. 2B , #8 to 11), which were cloned into a reporter plasmid (kb) are relative to the transcription start site of vHnf1 (+1). All fragments except the BAC clone (construct #1) were cloned upstream the lacZ reporter gene driven by the human β-globin minimal promoter. The BAC clone was co-injected with a reporter construct containing the lacZ gene under the control of the vHnf1 promoter. In constructs #5, 6 and 7 the black square represents a retinoic acid response element (mutated in construct #6) and the two black circles MAF-binding sites (mutated in construct #7). The transcriptional activity of the elements was estimated from the X-gal staining of transgenic or in ovo electroporated embryos. In the tables, (+) and (−) indicate the presence and absence of β-galactosidase activity in the neural tube of in ovo electroporated chick embryos, (n) the total number of E8 transgenic mouse embryos analyzed and (r5-r6) and (sc) the number of embryos expressing β-galactosidase in r5 and r6 and in the spinal cord, respectively. For construct #5, among six transgenic embryos expressing a high level of β-galactosidase in r5-r6, two were also strongly positive in the spinal cord, whereas the others showed lower levels of expression in this territory. nd, Not determined.
containing the lacZ gene driven by a human β-globin minimal promoter (Fig. 2B ). In the absence of an external transcriptional enhancer, this reporter plasmid does not lead to significant β-galactosidase expression in the chick neural tube following in ovo electroporation (Giudicelli et al., 2003) . Fragments #8 and 9 showed no activity in this assay (data not shown), whereas fragments #10 and 11 led to the activation of the lacZ reporter, in the entire neural tube for fragment #10 (Fig. 1D) , and caudally to the prospective r4/r5 boundary (level of the anterior border of the otic vesicle) for fragment #11 (Fig. 1E) . These data suggested that fragments #10 and 11 contained functional enhancer elements.
Identification of a vHnf1 r5-r6/spinal cord enhancer
To localize possible cis-acting elements present within fragments #10 and 11, we compared the sequences of both fragments with the orthologous regions in the mouse genome, searching for conserved non-coding sequences (CNS). CNS were identified within each fragment (Fig. 3A) . Fragment #10 contains two CNS located in the fourth intron, 200 and 800 bp long respectively. The two corresponding mouse sequences were subcloned in a unique fragment, #3, from the BAC. Fragment #10 also contains another, smaller CNS (120 bp) located in the eighth intron (Fig. 3A) , which transcriptional enhancing activity was not assessed. Fragment #11 contains a unique CNS 250 bp long (Fig. 3A) . The corresponding mouse sequence was subcloned in fragment #2 from the BAC. β-globin Promoter-lacZ reporter plasmids carrying fragment #2 or 3 were tested by in ovo electroporation and mouse transgenesis to determine whether the fragments carry enhancer activities ( Fig. 2A) . Surprisingly, although construct #2 recapitulated the restricted pattern observed with construct #11 by in ovo electroporation, it did not lead to any lacZ expression in mouse transgenic embryos (n = 10, Fig. 2A and data not shown). To establish that we had not missed a functional enhancer within fragment #11 that was not sufficiently conserved, we also tested fragment #11 in transgenic embryos. Again no activity was detected (n = 8, Fig. 2A ). We have already observed this type of situation in the case of several elements (Chomette et al., 2006; Ghislain et al., 2003 and data not shown). It might reflect a lack of stringency in the chick electroporation assay that reveals the presence of regulatory elements normally active in other tissues or stages, rather than reveal differences between mouse and chick regulation since the same behavior is observed with ciselements from both species. We have therefore not further analyzed fragment #2.
In contrast, construct #3 gave consistent results in both assays: it promoted efficient expression of the reporter in the hindbrain up to the r4/r5 boundary and in the spinal cord, with a decreasing gradient toward the node (3 out of 4 transgenic embryos, Figs. 1C and F, 2A) . In addition, the orthologous chick sequence led to the same activation pattern by in ovo electroporation (construct #12, Fig. 1G ). These data indicate that we have identified a conserved DNA sequence that functions as a neural transcriptional enhancer in both chick and mouse and directs an expression pattern similar to that of vHnf1. The fact that the larger chick fragment (#10) generated a less restricted pattern in the chick electroporation assay might be due to the presence of additional cis-acting sequences in fragment #10 and to the relaxed character of this assay as discussed above.
To further analyze the activity of construct #3 and in particular to determine the time course of reporter gene expression, we generated three mouse transgenic lines carrying this construct. Their analysis led to identical results: β-galactosidase activity was first detected around the 0-2 somite stage (ss) in the neural tube posterior to the otic sulcus, a pattern identical to that of endogenous gene, although vHnf1 mRNA accumulation was observed slightly earlier (Fig. 3, compare B, C to G, H; see also Figs. 6A, E). At 4 ss the anterior limit of X-gal staining was shown to correspond to the r4/r5 boundary, similar to the endogenous gene ( Fig. 3I and Sirbu et al., 2005) , as indicated by a common rostral limit with the r5 Krox20 domain ( Fig. 3D and insert) . At the 6 ss the β-galactosidase-and Krox20-positive domains still largely overlapped in r5, indicating that the anterior limit of transgene expression lied within this rhombomere, close to the r4/r5 boundary (Fig. 3E) , whereas the vHnf1 expression domain had already retracted, as shown by the very limited overlap with Krox20 in r5 (Fig. 3J) . At the 8-10 ss the anterior limit of transgene expression had also clearly regressed posteriorly within r5 as indicated by double labeling with the Hoxb1 r4 marker (Fig. 3F) , while vHnf1 was not expressed in r5 anymore and was restricted to the dorsal neural tube (Fig. 3K) . Analysis of transgene expression at later stages (up to E12.5) revealed a neural tube profile similar to that of the endogenous gene (Barbacci et al., 1999; Coffinier et al., 1999) .
In conclusion, fragment #3 appears to carry an enhancer activity capable of recapitulating vHnf1 expression in r5/r6 and the spinal cord between E8 and E12.5. The differences that are observed with the vHnf1 mRNA profile (slightly delayed activation around E8 and delayed regression from r5 and from the ventral neural tube) are likely to be accounted for by the time required to accumulate β-galactosidase and by the higher stability of the protein, respectively. Therefore, fragment #3 contains a cis-acting regulatory element likely to be responsible for vHnf1 neural expression.
A minimal neural enhancer responsible for the initiation of vHnf1 expression
To precisely define the limits of the r5-r6/spinal cord enhancer, we tested the activity of two subfragments carrying the largest of the two conserved regions present in fragment #3 (Fig. 4A) . Fragment #4 (800 bp) and fragment #5 (550 bp) were cloned in the expression construct and assayed by in ovo electroporation and mouse transgenesis. Fragment #4 led to the same pattern of reporter expression as fragment #3 in both assays, except that the level of expression was higher when tested by electroporation ( Figs. 2A and 4B , C, E, F). Construct #5 gave the same profile as construct #4 after chick electroporation (Fig. 4G ), but a difference was noticed in transgenic embryos: among the six embryos that expressed the reporter, X-gal labeling was strong in r5-r6 and the spinal cord for two of them ( Figs. 2A and 5G ), like constructs #3 and 4. In contrast, in the other four embryos, whereas reporter expression was strong in r5 and r6, it was reduced in the spinal cord (Figs.  2A, 4D and 7D ). These data suggest that fragment #4 contains all the necessary sequences for the activity of fragment #3 and for normal neural expression of vHnf1. For this reason we did not investigate the activity of the other block of conserved sequences (200 bp) within fragment #3 (Fig. 4A) . Fragment #5 has conserved the r5-r6 enhancer activity but is likely to have lost some sequences modulating the efficiency of transcriptional activation in the spinal cord.
Developmental transcription factor genes are often subjected to direct autoregulation (Chomette et al., 2006) . It was therefore important to determine whether the neural enhancer identified in Fig. 3 . The neural enhancer recapitulates vHnf1 expression during hindbrain segmentation. (A) Homology plots between mouse and chick sequences within chick fragments #10 and #11 (Fig. 2 ) generated using the Pipmaker software. The horizontal axis represents the mouse sequence in kilobases (k) and the vertical axis the percentage of homology between mouse and chick sequences. Mouse sequences between 0 and 44 kb and between 43 and 80 kb are orthologous to chick fragments #10 and 11, respectively. Only homology superior to 50% is shown. Exons (Ex.) are indicated by black boxes and two fragments containing highly conserved noncoding sequences (constructs #2 and 3) are delineated by blue lines. (B-F) Dorsal views of embryos from a mouse line transgenic for construct #3 and analyzed for β-galactosidase activity by X-gal staining. (G-K) Dorsal views of mouse embryos analyzed by in situ hybridization with a vHnf1 probe (purple). Rhombomeres (r) were identified by in situ hybridization with probes specific for Krox20 (marks r3 and r5 in purple in panels D and E and in orange in panels J and K) and Hoxb1 (F, marks r4 and spinal cord in purple). Inset in panel D corresponds to a flat mount of the indicated area. The somite stages (ss) are indicated. OS, otic sulcus. fragment #4 was responsible for the initiation of vHnf1 expression or was simply acting as an autoregulatory element. To investigate the possibility of a direct autoregulation, we analyzed element #4 nucleotide sequence for the presence of vHNF1-binding sites with a known weight matrix (Tronche et al., 1997 ). We identified a unique possible vHNF1-binding site that did not perfectly match the matrix. Furthermore, band shift experiments performed with an oligonucleotide carrying this putative site did not lead to any specific retarded band in presence of cellular extracts containing vHNF1 (data not shown). These data suggest that fragment #4 does not contain any functional vHNF1-binding site and is not a direct target of vHNF1. This conclusion was further supported by in ovo coelectroporation experiments with construct #4 and a vHnf1 expression plasmid, which showed no modification of reporter expression in presence of exogenous vHNF1 (data not shown).
In conclusion, altogether our data indicate that we have delimited a minimal vHnf1 neural enhancer (fragment #4) and a smaller "core" element (fragment #5) that preserves most of the activity of the larger enhancer. This enhancer does not behave as a simple autoregulatory element and is therefore likely to be responsible for the initiation of vHnf1 expression in r5-r6 and the spinal cord.
Direct control of vHnf1 expression by RA signaling
As discussed above, several recent studies, involving lossand gain-of-function experiments in the mouse (Sirbu et al., 2005) and zebrafish (Hernandez et al., 2004 (Hernandez et al., , 2007 Maves and Kimmel, 2005) , have indicated that vHnf1 expression in the neural tube is controlled by RA signaling. We therefore investigated the possibility that this regulation is mediated by the neural enhancer. We first analyzed the consequences of an increase in the level of RA on the activity of the enhancer. It has been shown previously that administration of a dose of 20 μg/g of RA to pregnant females at 7.5 dpc resulted in an anterior shift of vHnf1 expression in the hindbrain of E8.25 embryos (Sirbu et al., 2005) . We observed a similar modification in reporter gene expression in the transgenic line carrying construct #3, with a limited shift at E8 (n = 2; Figs. 5B, C) and a significant one at E8.5 (n = 4; Figs. 5D, E). These data indicate that the vHnf1 neural enhancer is ectopically activated in anterior territories and therefore responds to RA in a manner similar to the endogenous gene.
This observation raised the possibility that the neural enhancer might constitute a direct target for RA signaling. We therefore performed an in silico search for retinoic acid response elements (RARE) within the sequence of fragment #4. Only one putative RARE was identified, belonging to the DR5 type, composed of two direct repeats separated by five unspecified base pairs (Fig. 5A ). This site is located within the core enhancer delimited by fragment #5 and is highly conserved within vertebrate species (Supplementary Fig. 1 ). This type of RARE is supposed to bind heterodimers of the nuclear hormone receptor (RAR) and of its co-receptor (RXR) (Mader et al., 1993) . To demonstrate that this sequence constitutes a bona fide RARE, we performed band shift experiments using a 65-bp oligonucleotide covering the site and nuclear extracts from COS-7 cells expressing both RARβ and RXRα proteins. In the presence of RARβ/RXRα extract a specific retarded band was observed and supershifted by antibodies directed against RARβ or RXRα (Fig. 5F ). Furthermore, mutation of three nucleotides within each direct repeat abolished binding (Figs. 5A, F) . These data establish that the vHnf1 neural enhancer contains a RARE that is able to bind RAR/RXR heterodimers in vitro.
To determine whether this RARE plays a functional role in vivo, we tested the effect of the same mutations on the activity of the enhancer (construct #6). The mutated enhancer was almost completely inactive in both mouse transgenesis and in ovo electroporation (Figs. 2A, 5G-J) . Out of nine transgenic embryos, only one showed a residual reporter expression in r5 and r6 ( Fig. 2A and data not shown) . These data demonstrate that the vHnf1 neural enhancer constitutes a direct target of RA receptors and that RA signaling directly controls initiation of vHnf1 expression through this enhancer.
MAFB is involved in the modulation of vHnf1 expression in r5 and r6
In search for additional regulators of vHnf1, we investigated the possible involvement of MAFB. MAFB belongs to the MAF family of transcription factors, is expressed in r5 and r6 and plays an essential role the development of these rhombomeres (Cordes and Barsh, 1994; Frohman et al., 1993; Manzanares et al., 1999; Moens et al., 1996) . MafB activation in r5 and r6 occurs later than that of vHnf1 and it has actually been shown to require vHNF1 (Hernandez et al., 2004; Kim et al., 2005; Wiellette and Sive, 2003) . However, this does not exclude the possibility of a feedback of MAFB on vHnf1 expression. To investigate this possibility, we analyzed vHnf1 expression in the kreisler mutant, in which MafB expression is eliminated in r5-r6. In this mutant the r5/r6 territories are replaced by a smaller, so-called rX domain that retains some r6 properties (Frohman et al., 1993; Manzanares et al., 1999; Moens et al., 1996) . In kreisler embryos vHnf1 expression was normally activated posterior to the otic sulcus at 0 ss (Figs. 6A and B) . However at 5 ss the level of vHnf1 expression was slightly reduced anteriorly, at the expected level of rX, as compared to wild-type embryos in r5 and r6, whereas the spinal cord expression was not affected (Figs. 6C and D) . These data confirm that MAFB is not involved in the initial activation of vHnf1 and indicate that, in contrast, it plays a role in a later slight up-regulation in r5 and r6.
Transfer of the construct #3 transgene into a homozygous kreisler background showed that although reporter gene expression was normally initiated at around 0 ss, it was expressed at reduced levels at the level of the rX domain at 6 and 10 ss as compared to controls in r5 and r6 (Figs. 6E-J′) . These data suggest that the neural enhancer mediates the modulation of vHnf1 by MAFB. Consistently we observed that in chick co-electroporation experiments the enhancer/reporter construct is activated by exogenous MAFB rostrally to its normal domain of activity (Figs. 6K and L) . The expression of the lacZ reporter driven by the vHnf1 enhancer (construct #3) was analyzed by X-gal staining at the indicated somite stages in wild-type (E, G, I) or kreisler mutant (F, H, J) mouse embryos. Panels G′-J′ show higher magnifications of the r5-r6/rX regions from the corresponding pictures. (K, L) Chick embryos analyzed by X-gal staining after coelectroporation with construct #5 together with expression vectors for versions of MAFB carrying a mutation preventing DNA binding (R22E, Kataoka et al., 1994) (K) or wild type (L). In the presence of ectopic wild-type MAFB, β-galactosidase expression is detected in a territory anterior to the normal domain of activity of the enhancer (brackets), whereas a mutant MAFB (R22E) that cannot bind to DNA has no effect. OS, otic sulcus; r, rhombomere; rX, transformed territory replacing r5 and r6 in the kreisler mutant; OV, otic vesicle.
Direct regulation of vHnf1 by different MAF-related factors
The implication of MAFB in the modulation of the activity of the vHnf1 neural enhancer prompted us to investigate whether this effect involved direct binding of this transcription factor to the enhancer. Band shift experiments were performed on fragment #5 using extracts from control and MafB expressing bacteria. Multiple retarded bands were observed (indicated by brackets in Fig. 7B ), which could be specifically competed by an oligonucleotide carrying a T-MARE consensus binding site. Additional band shift experiments performed on overlapping subfragments allowed the localization of the binding sites within a 200-bp region at the 5′ end of fragment #5 (data not shown). This region was subsequently subjected to DNAse I footprinting analysis on both strands using the same bacterial extracts. This revealed the existence of two domains (designated MAF1 and MAF2) specifically protected by MAFB (Fig. 7C) . Analysis of the corresponding nucleotide sequences revealed the presence in each of them of a motif with high similarity to a half so-called T-MARE consensus site (Figs. 7A and C), which has previously been shown to act as a functional MAF-binding site (Manzanares et al., 1997 (Manzanares et al., , 2002 .
To determine whether these MAF-binding sites were playing a role in enhancer activity, we introduced mutations in both sites (Fig. 7A) and first analyzed their effect by gel retardation. Although binding was not completely abolished, it was severely reduced (Fig. 7B) . A version of construct #5 carrying the MAF1 and MAF2 mutations (construct #7) was then used to generate transgenic embryos. Whereas the wild-type enhancer leads to specific lacZ expression in r5, r6 and spinal cord (Figs. 4D, 5G,  7D ), the mutated version was completely inactive in most transgenic embryos (9 out of 10) ( Figs. 2A and 7E ) and the only positive embryo showed a very low level of expression (data not shown). This latter activity might be related to the residual MAF binding of the mutated enhancer. In any case these experiments demonstrate that the two identified MAF sites play an essential role in the activity of the vHnf1 neural enhancer, not only in r5-r6 but also in the spinal cord. This effect cannot be mediated by MAFB and therefore suggests that other factor(s) binding to the half T-MARE site, which might also belong to the MAF family, are required for vHnf1 expression in the hindbrain and the spinal cord.
Discussion
In this paper we have investigated the regulation of vHnf1, an essential component of the gene network governing caudal hindbrain segmentation by identifying a cis-acting element responsible for its expression in the neural tube. Analysis of this element revealed that it integrates direct inputs from the RA signaling cascade and from MAF-related factors. Our data allow us to propose a model accounting for the initiation and maintenance phases of vHnf1 expression and for the establishment of the r4/r5 boundary.
A conserved, intronic enhancer controls vHnf1 expression in the developing neural tube By combining nucleotide sequence comparisons and functional in vivo assays, we have been able to scan a region of 193 kb around and within the mouse vHnf1 gene and identify an 800-bp sequence located within the fourth intron that is able to drive transcription of a promoter/reporter construct, closely recapitulating the pattern of vHnf1 expression in the neural tube between E8 and E12.5. This enhancer was shown to mediate the regulation of vHnf1 by RA signaling and is likely to constitute the essential cis-acting element governing vHnf1 expression in the neural tube. The comparison of various vertebrate genome sequences shows that this enhancer is strongly conserved in all vertebrate species tested ( Supplementary Fig. S1 and data not shown). Indeed it contains a 94-bp Ultra Conserved Region (UCR) that was previously identified by Sandelin et al. (2004) (see Supplementary Fig. S1 ). This strong evolutionary conservation of the enhancer sequence is fully consistent with the equally strong conservation of the vHnf1 expression pattern in the developing neural tube among vertebrates (Aragon et al., 2005; Lecaudey et al., 2004; Sirbu et al., 2005; Sun and Hopkins, 2001) , suggesting that this element plays a similar role in regulating vHnf1 transcription in all vertebrates.
The vHnf1 enhancer integrates direct inputs from RA signaling and MAF-related factors Analysis of the vHnf1 neural enhancer revealed that it contains at least two types of essential motifs, a RARE and two half T-MARE sites. We have shown that the activity of the enhancer is modulated by exogenous RA in a manner similar to the endogenous vHnf1 gene and that the integrity of the RARE is absolutely required for its activity in the hindbrain and the spinal cord at least between 0 and 8 ss. This suggests that the RARE is required in particular for the initiation phase of vHnf1 expression. Altogether our data indicate that the neural enhancer is mediating direct regulation of vHnf1 by RA signaling and that the RA signal is constantly required for expression until 8 ss at least.
The analysis of the half T-MARE sites revealed important additional features of the regulation of vHnf1. Their integrity is also absolutely necessary for the activity of the enhancer as measured between 0 and 10 ss, suggesting that they are constantly required from the initiation of vHnf1 expression. Furthermore, mutation of these motifs abolishes enhancer activity in both the hindbrain and the spinal cord. In contrast inactivation of MAFB does not affect initiation of vHnf1 expression but simply leads to a later, slight down-regulation in r5 and r6. These data suggest the existence of at least two phases in the regulation of vHnf1 expression, initiation and maintenance, which involve different MAF factors. In both the hindbrain and spinal cord initiation is strictly dependent on the binding to the enhancer of both an RAR/RXR heterodimer and (a) T-MARE-binding factor(s), different from MAFB. In the maintenance period vHnf1 expression is up-regulated in r5 and r6 by MAFB. During this phase vHnf1 expression is still strictly dependent on the binding of the RAR/RXR receptor complex and of at least another MAF-related factor in the hindbrain and the spinal cord. These data therefore indicate that the neural enhancer integrates at least three inputs (RA signaling, MAFB and another MAF-related factor) to specify the dynamics of vHnf1 pattern of expression. They also suggest that the RAR/ RXR complex and MAF factors are able to synergistically cooperate to activate the vHnf1 enhancer. Interestingly RARα and RARγ have been shown to directly interact with the leucine zipper region of another factor, p45/NF-E2, in a liganddependent manner and this interaction potentiates RAR transcriptional activity (Cheng et al., 1997) . Since MafB is itself directly up-regulated by vHNF1 (Kim et al., 2005) , our data provide evidence for the existence of an indirect autoregulatory loop controlling vHnf1 expression and a possible explanation for the necessity of MAFB activity for robust MafB induction by vHNF1 and FGF (Hernandez et al., 2004) . However, this autoregulatory loop requires RA signaling, which might explain why co-electroporation of the neural enhancer with a vHnf1 expression vector does not lead to rostral, ectopic activation of the enhancer or of the endogenous gene (data not shown and Aragon et al., 2005) . Finally, as indicated above, the neural enhancer contains other highly conserved sequences that are also likely to bind additional transcription factors involved in vHnf1 regulation. A detailed mutagenesis will be required to uncover these putative regulators.
A model for vHnf1 regulation and positioning of the r4/r5 boundary Our understanding of the characteristics of the neural enhancer allows us to propose a molecular model for vHnf1 regulation, which itself impacts on the patterning of the caudal hindbrain. Our proposal further builds on models recently developed (Hernandez et al., 2007; Sirbu et al., 2005) . vHnf1 is expressed in the posterior neural tube with an initial rostral limit that has been shown to position the r4/r5 boundary (Hernandez et al., 2004 (Hernandez et al., , 2007 Lecaudey et al., 2004) . It has been proposed that it is the level of RA signaling that defines the anterior extension of vHnf1 expression (Hernandez et al., 2007; Sirbu et al., 2005) . During early developmental stages, RA is synthesized by RALDH2 and the recently identified RA synthesizing enzyme, CYP1B1 (Chambers et al., 2007; Niederreither et al., 2000) , and at the 0 ss RA levels are supposed to be low rostral to the r4/r5 boundary due to the expression the CYP26A1 and CYP26C1 RA degradation enzymes (Hernandez et al., 2007) . Since RXRs and RARs are widely expressed at that stage in the hindbrain (for a review, see Glover et al., 2006) , vHnf1 expression may reflect RA levels. Similarly the progressive caudal retraction of the vHnf1 expression domain from the hindbrain is likely to reflect the progressive caudal reduction in RA levels due to the activation of the third CYP26 enzyme, CYP26B1 (Hernandez et al., 2007; MacLean et al., 2001 ).
However at the onset of vHnf1 expression, at around 70% epiboly in the zebrafish and E7.8 in the mouse, RA signaling is effective in prospective r4 as shown by the RA-dependent activation of Hoxa1 and Hoxb1 (Langston and Gudas, 1992; Marshall et al., 1994) and by the expression pattern of RARElacZ constructs in transgenic mice (Rossant et al., 1991; Sirbu et al., 2005) . To explain the restriction of vHnf1 caudal to the prospective r4/r5 boundary, at least three types of explanations can be envisaged. (i) The first one relies on a possible differential sensitivity of RAREs associated with different threshold levels of RA signaling in r4 and in more caudal regions of the neural tube. Hence it was hypothesized that the difference in the rostral expression limits between Hoxb1 and vHnf1 was due to the presence of a DR2 RARE in Hoxb1 and a lower affinity DR1 in the promoter of vHnf1 (Sirbu et al., 2005) . However, this is not likely since the vHnf1 promoter is not able to drive specific neural tube expression (S. Cereghini, personal communication) and since the vHnf1 neural enhancer contains a functional DR5 RARE. (ii) Another possibility is that the absence of expression of vHnf1 in r4 is due to repression by another factor. Indeed, loss-and gain-of-function experiments in the zebrafish have shown that Iro7 (also known as Irx7), a member of the Iroquois transcription factor family, acts as a repressor of vHnf1 expression and indeed participates in positioning its anterior limit of expression (Lecaudey et al., 2004) . However, the mode of action of this factor is not known. We have used an Iroquois binding weight matrix (Bilioni et al., 2005) to search for binding sites within the vHnf1 neural enhancer without success (data not shown), suggesting that Iro7 is not directly acting on the enhancer. The absolute requirement of the two half T-MARE sites for the activity of the neural enhancer raises the possibility that Iro7 might act by repression of the MAF-related factor that binds to these sites. (iii) A third hypothesis, not exclusive with the previous one, is that the MAF-related factor is not directly specifying the domain of activation of vHnf1 but rather its timing. In this case, if activation by the MAF-related factor occurs at the time that RA signaling has regressed to the level of the prospective r4/r5 boundary, this would establish the rostral limit of vHnf1 expression at this level. Validation of these latter hypotheses will require the identification of the factors binding to the vHnf1 half T-MARE sites. Despite limited knowledge on Maf family expression patterns, one member attracted our attention, MafA, since at the 8 ss stage in the chick embryo, it is expressed along the entire neural tube with a much lower level in r4 and an upregulation in r5 and r6 (see Fig. 2C in Lecoin et al., 2004) . However, our analysis in the mouse embryo did not reveal a sufficiently early expression to be consistent with an implication in the initial activation of vHnf1 (data not shown). Therefore, further work will be required to find the factors binding to the half T-MARE sites and this may not be a trivial issue, since MAF factors can heterodimerize with various leucine zipper proteins.
